{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:52Z","timestamp":1791207352468,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venetoclax is a highly potent, selective BCL2 inhibitor capable of inducing apoptosis in cells dependent on BCL2 for survival. Most myeloma is MCL1-dependent; however, a subset of myeloma enriched for translocation t(11;14) is codependent on BCL2 and thus sensitive to venetoclax. The biology underlying this heterogeneity remains poorly understood. We show that knockdown of cyclin D1 does not induce resistance to venetoclax, arguing against a direct role for cyclin D1 in venetoclax sensitivity. To identify other factors contributing to venetoclax response, we studied a panel of 31 myeloma cell lines and 25 patient samples tested for venetoclax sensitivity. In cell lines, we corroborated our previous observation that BIM binding to BCL2 correlates with venetoclax response and further showed that knockout of BIM results in decreased venetoclax sensitivity. RNA-sequencing analysis identified expression of B-cell genes as enriched in venetoclax-sensitive myeloma, although no single gene consistently delineated sensitive and resistant cells. However, a panel of cell surface makers correlated well with ex vivo prediction of venetoclax response in 21 patient samples and may serve as a biomarker independent of t(11;14). Assay for transposase-accessible chromatin sequencing of myeloma cell lines also identified an epigenetic program in venetoclax-sensitive cells that was more similar to B cells than that of venetoclax-resistant cells, as well as enrichment for basic leucine zipper domain\u2013binding motifs such as BATF. Together, these data indicate that remnants of B-cell biology are associated with BCL2 dependency and point to novel biomarkers of venetoclax-sensitive myeloma independent of t(11;14).<\/jats:p>","DOI":"10.1182\/blood.2020007899","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T03:53:57Z","timestamp":1614657237000},"page":"3604-3615","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-2338","authenticated-orcid":false,"given":"Vikas A.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M.","family":"Matulis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Shirasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Jaye","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Winship Cancer Institute of Emory University, Atlanta, GA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-7399","authenticated-orcid":false,"given":"Jonathan J.","family":"Keats","sequence":"additional","affiliation":[{"name":"Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Oberlton","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha S.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-1607","authenticated-orcid":false,"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard T.","family":"Heffner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9436-8815","authenticated-orcid":false,"given":"Lawrence H.","family":"Boise","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"issue":"6","key":"2021071217040773400_B1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17474086.2017.1326814","article-title":"How is patient care for multiple myeloma advancing?","volume":"10","author":"Genadieva Stavric","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"2021071217040773400_B2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2021071217040773400_B3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol Cell"},{"issue":"18","key":"2021071217040773400_B4","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/emboj.2011.307","article-title":"Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases","volume":"30","author":"Strasser","year":"2011","journal-title":"EMBO J"},{"issue":"1-2","key":"2021071217040773400_B5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2013.09.015","article-title":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","volume":"155","author":"Scarf\u00f2","year":"2013","journal-title":"Immunol Lett"},{"issue":"7626","key":"2021071217040773400_B6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"1","key":"2021071217040773400_B7","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"2021071217040773400_B8","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"2021071217040773400_B9","first-page":"224","article-title":"Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"12","author":"Ng","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"2021071217040773400_B10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2021071217040773400_B11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"2021071217040773400_B12","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/ni.3519","article-title":"Plasma cell differentiation is coupled to division-dependent DNA hypomethylation and gene regulation","volume":"17","author":"Barwick","year":"2016","journal-title":"Nat Immunol"},{"issue":"6","key":"2021071217040773400_B13","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"issue":"24","key":"2021071217040773400_B14","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1073\/pnas.1005256107","article-title":"BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs","volume":"107","author":"Carrington","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2021071217040773400_B15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells [published correction appears in Nat Immunol. 2013;14(8):877]","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"issue":"14","key":"2021071217040773400_B16","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2021071217040773400_B17","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2011-01-327197","article-title":"Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL\/Bcl-2 in Mcl-1-expressing myeloma cells","volume":"118","author":"Morales","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2021071217040773400_B18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"14","key":"2021071217040773400_B19","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"issue":"22","key":"2021071217040773400_B20","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2021071217040773400_B21","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2021071217040773400_B22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2021071217040773400_B23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/leu.2015.184","article-title":"BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics","volume":"30","author":"Touzeau","year":"2016","journal-title":"Leukemia"},{"issue":"14","key":"2021071217040773400_B24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2021071217040773400_B25","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14251","article-title":"BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma","volume":"179","author":"Dousset","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2021071217040773400_B26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood.V98.3.805","article-title":"Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells","volume":"98","author":"Grad","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2021071217040773400_B27","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/blood-2007-10-116889","article-title":"BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma","volume":"111","author":"Morales","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2021071217040773400_B28","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41375-018-0374-8","article-title":"Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma","volume":"33","author":"Matulis","year":"2019","journal-title":"Leukemia"},{"issue":"6166","key":"2021071217040773400_B29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.1246981","article-title":"Genetic screens in human cells using the CRISPR-Cas9 system","volume":"343","author":"Wang","year":"2014","journal-title":"Science"},{"issue":"1","key":"2021071217040773400_B30","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2021071217040773400_B31","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41467-018-04234-4","article-title":"B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation","volume":"9","author":"Barwick","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2021071217040773400_B32","doi-asserted-by":"crossref","first-page":"27030","DOI":"10.1038\/srep27030","article-title":"ATAC-seq on biobanked specimens defines a unique chromatin accessibility structure in na\u00efve SLE B cells","volume":"6","author":"Scharer","year":"2016","journal-title":"Sci Rep"},{"issue":"25","key":"2021071217040773400_B33","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2021071217040773400_B34","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.emboj.7601126","article-title":"Bcl-2 changes conformation to inhibit Bax oligomerization","volume":"25","author":"Dlugosz","year":"2006","journal-title":"EMBO J"},{"issue":"20","key":"2021071217040773400_B35","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1158\/0008-5472.CAN-08-1329","article-title":"Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma","volume":"68","author":"Mori","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"2021071217040773400_B36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ni.3154","article-title":"Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells","volume":"16","author":"Shi","year":"2015","journal-title":"Nat Immunol"},{"issue":"2","key":"2021071217040773400_B37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2002-10-3161","article-title":"Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation","volume":"102","author":"Tarte","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2021071217040773400_B38","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2021071217040773400_B39","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2021071217040773400_B40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri3470","article-title":"Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks","volume":"13","author":"Murphy","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2021071217040773400_B41","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1182\/blood-2014-05-578732","article-title":"The Tao of myeloma","volume":"124","author":"Boise","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2021071217040773400_B42","first-page":"3131","article-title":"Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed\/refractory multiple myeloma","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2021071217040773400_B43","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/26\/3604\/1813177\/bloodbld2020007899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/26\/3604\/1813177\/bloodbld2020007899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T14:52:29Z","timestamp":1671461549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/26\/3604\/475387\/Venetoclax-sensitivity-in-multiple-myeloma-is"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":43,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2021,3,1]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020007899","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}